The fact that everything looks different doesn't mean that all has changed...
Biblio
Export 30 results:
Author Title Type [ Year
] Filters: First Letter Of Last Name is P [Clear All Filters]
. Fetal-like reversion in the regenerating intestine is regulated by mesenchymal asporin. Cell Stem Cell [Internet]. 2025;32(4):613 - 626.e8. https://www.sciencedirect.com/science/article/pii/S1934590925000487
. Fetal-like reversion in the regenerating intestine is regulated by mesenchymal asporin. Cell Stem Cell [Internet]. 2025;32(4):613 - 626.e8. https://www.sciencedirect.com/science/article/pii/S1934590925000487
. Targeting Bacterial and Human Levodopa Decarboxylases for Improved Drug Treatment of Parkinson's Disease: Discovery and Characterization of New Inhibitors. European Journal of Pharmaceutical Sciences [Internet]. 2025;:107133. https://authors.elsevier.com/sd/article/S0928-0987(25)00132-0
Reunanen et al. 2025 - Targeting Bacterial and Human Levodopa Decarboxylases for Improved Drug Treatment of Parkinson’s Disease (1.18 MB)
Reunanen et al. 2025 - Targeting Bacterial and Human Levodopa Decarboxylases for Improved Drug Treatment of Parkinson’s Disease (1.18 MB). Targeting Bacterial and Human Levodopa Decarboxylases for Improved Drug Treatment of Parkinson's Disease: Discovery and Characterization of New Inhibitors. European Journal of Pharmaceutical Sciences [Internet]. 2025;:107133. https://authors.elsevier.com/sd/article/S0928-0987(25)00132-0 Reunanen et al. 2025 - Targeting Bacterial and Human Levodopa Decarboxylases for Improved Drug Treatment of Parkinson’s Disease (1.18 MB)
Reunanen et al. 2025 - Targeting Bacterial and Human Levodopa Decarboxylases for Improved Drug Treatment of Parkinson’s Disease (1.18 MB). Targeting Bacterial and Human Levodopa Decarboxylases for Improved Drug Treatment of Parkinson's Disease: Discovery and Characterization of New Inhibitors. European Journal of Pharmaceutical Sciences [Internet]. 2025;:107133. https://authors.elsevier.com/sd/article/S0928-0987(25)00132-0 Reunanen et al. 2025 - Targeting Bacterial and Human Levodopa Decarboxylases for Improved Drug Treatment of Parkinson’s Disease (1.18 MB)
Reunanen et al. 2025 - Targeting Bacterial and Human Levodopa Decarboxylases for Improved Drug Treatment of Parkinson’s Disease (1.18 MB). The relationship between the secondary vascular system and the lymphatic vascular system in fish. Biological Reviews [Internet]. 2024;. https://onlinelibrary.wiley.com/doi/10.1111/brv.13114 Panara et al. - 2024 - The relationship between the secondary vascular system and the lymphatics vascular system in fish (3.51 MB)
Panara et al. - 2024 - The relationship between the secondary vascular system and the lymphatics vascular system in fish (3.51 MB). Study of the Synergistic Immunomodulatory and Antifibrotic Effects of Dual-Loaded Budesonide and Serpine1 siRNA Lipid–Polymer Nanoparticles Targeting Macrophage Dysregulation in Tendinopathy. ACS Applied Materials & Interfaces [Internet]. 2024;16(15):18643 - 18657. https://pubs.acs.org/doi/10.1021/acsami.4c02363 López-Cerdá et al. - 2024 - Study of the Synergistic Immunomodulatory and Antifibrotic Effects of Dual-Loaded Budesonide [...] (7.06 MB)
López-Cerdá et al. - 2024 - Study of the Synergistic Immunomodulatory and Antifibrotic Effects of Dual-Loaded Budesonide [...] (7.06 MB). Functional Dissection of the CCBE1 Protein: A Crucial Requirement for the Collagen Repeat Domain. Circ Res [Internet]. 2015;116(10):1660-1669. http://circres.ahajournals.org/content/116/10/1660.long
. Functional Dissection of the CCBE1 Protein: A Crucial Requirement for the Collagen Repeat Domain. Circ Res [Internet]. 2015;116(10):1660-1669. http://circres.ahajournals.org/content/116/10/1660.long
. Structural and mechanistic insights into VEGF receptor 3 ligand binding and activation. Proceedings of the National Academy of Sciences of the United States of America [Internet]. 2013;110(32):12960 - 12965. http://www.pnas.org/content/110/32/12960.long
. Structural determinants of growth factor binding and specificity by VEGF receptor 2. Proceedings of the National Academy of Sciences of the United States of America [Internet]. 2010;107(6):2425 - 30. http://view.ncbi.nlm.nih.gov/pubmed/20145116 Veli-Matti Leppänen et al. PNAS 2010 (1 MB) Veli-Matti Leppänen et al. PNAS 2010, supporting information (2.23 MB)
Veli-Matti Leppänen et al. PNAS 2010 (1 MB) Veli-Matti Leppänen et al. PNAS 2010, supporting information (2.23 MB). Suppressive effects of vascular endothelial growth factor-B on tumor growth in a mouse model of pancreatic neuroendocrine tumorigenesis. PLoS ONE [Internet]. 2010;5(11):e14109. http://view.ncbi.nlm.nih.gov/pubmed/21124841 Imke Albrecht et al., PLoS One 2010 (3.37 MB)
Imke Albrecht et al., PLoS One 2010 (3.37 MB). Overexpression of vascular endothelial growth factor-B in mouse heart alters cardiac lipid metabolism and induces myocardial hypertrophy. Circ Res [Internet]. 2008;103(9):1018 - 26. http://view.ncbi.nlm.nih.gov/pubmed/18757827 Terhi Kärpänen et al., Circulation Research 2008 (898.27 KB) Terhi Kärpänen et al., Circulation Research 2008, supplement (1.56 MB)
Terhi Kärpänen et al., Circulation Research 2008 (898.27 KB) Terhi Kärpänen et al., Circulation Research 2008, supplement (1.56 MB). Reevaluation of the role of VEGF-B suggests a restricted role in the revascularization of the ischemic myocardium. Arterioscler Thromb Vasc Biol [Internet]. 2008;28(9):1614 - 20. http://view.ncbi.nlm.nih.gov/pubmed/18511699 Xuri Li et al., Arteriosclerosis, Thrombosis, and Vascular Biology 2008 (738.26 KB) Xuri Li et al., Arteriosclerosis, Thrombosis, and Vascular Biology 2008, data supplement (1012.6 KB)
Xuri Li et al., Arteriosclerosis, Thrombosis, and Vascular Biology 2008 (738.26 KB) Xuri Li et al., Arteriosclerosis, Thrombosis, and Vascular Biology 2008, data supplement (1012.6 KB). Distinct architecture of lymphatic vessels induced by chimeric vascular endothelial growth factor-C/vascular endothelial growth factor heparin-binding domain fusion proteins. Circ Res [Internet]. 2007;100(10):1468 - 75. http://view.ncbi.nlm.nih.gov/pubmed/17478733 Tuomas Tammela et al., Circulation Research 2007 (1.1 MB)
Tuomas Tammela et al., Circulation Research 2007 (1.1 MB). Pathogenesis of persistent lymphatic vessel hyperplasia in chronic airway inflammation. J Clin Invest [Internet]. 2005;115(2):247 - 57. http://view.ncbi.nlm.nih.gov/pubmed/15668734 Peter Baluk et al., Journal of Clinical Investigation 2005 (1.89 MB)
Peter Baluk et al., Journal of Clinical Investigation 2005 (1.89 MB). Pathogenesis of persistent lymphatic vessel hyperplasia in chronic airway inflammation. J Clin Invest [Internet]. 2005;115(2):247 - 57. http://view.ncbi.nlm.nih.gov/pubmed/15668734 Peter Baluk et al., Journal of Clinical Investigation 2005 (1.89 MB)
Peter Baluk et al., Journal of Clinical Investigation 2005 (1.89 MB). Vascular endothelial cell growth factor receptor 3-mediated activation of lymphatic endothelium is crucial for tumor cell entry and spread via lymphatic vessels. Cancer Res [Internet]. 2005;65(11):4739 - 46. http://view.ncbi.nlm.nih.gov/pubmed/15930292 Yulong He et al., Cancer Research 2005 (1.82 MB)
Yulong He et al., Cancer Research 2005 (1.82 MB). Vascular endothelial growth factor C is required for sprouting of the first lymphatic vessels from embryonic veins. Nat Immunol [Internet]. 2004;5(1):74 - 80. http://view.ncbi.nlm.nih.gov/pubmed/14634646 Marika Kärkkäinen et al., Nature Immunology 2004 (3.01 MB) Marika Kärkkäinen et al., Nature Immunology 2004, supplementary data 1 (1.27 MB) Marika Kärkkäinen et al., Nature Immunology 2004, supplementary data 2 (1.23 MB)
Marika Kärkkäinen et al., Nature Immunology 2004 (3.01 MB) Marika Kärkkäinen et al., Nature Immunology 2004, supplementary data 1 (1.27 MB) Marika Kärkkäinen et al., Nature Immunology 2004, supplementary data 2 (1.23 MB). Vascular endothelial growth factor C is required for sprouting of the first lymphatic vessels from embryonic veins. Nat Immunol [Internet]. 2004;5(1):74 - 80. http://view.ncbi.nlm.nih.gov/pubmed/14634646 Marika Kärkkäinen et al., Nature Immunology 2004 (3.01 MB) Marika Kärkkäinen et al., Nature Immunology 2004, supplementary data 1 (1.27 MB) Marika Kärkkäinen et al., Nature Immunology 2004, supplementary data 2 (1.23 MB)
Marika Kärkkäinen et al., Nature Immunology 2004 (3.01 MB) Marika Kärkkäinen et al., Nature Immunology 2004, supplementary data 1 (1.27 MB) Marika Kärkkäinen et al., Nature Immunology 2004, supplementary data 2 (1.23 MB). Intrinsic versus microenvironmental regulation of lymphatic endothelial cell phenotype and function. FASEB J [Internet]. 2003;17(14):2006 - 13. http://view.ncbi.nlm.nih.gov/pubmed/14597670 Tanja Veikkola et al., FASEB Journal 2006 (598.77 KB)
Tanja Veikkola et al., FASEB Journal 2006 (598.77 KB). Adenoviral expression of vascular endothelial growth factor-C induces lymphangiogenesis in the skin. Circ Res [Internet]. 2001;88(6):623 - 9. http://view.ncbi.nlm.nih.gov/pubmed/11282897 Bernd Enholm et al., Circulation Research 2001 (2.93 MB)
Bernd Enholm et al., Circulation Research 2001 (2.93 MB). Signalling via vascular endothelial growth factor receptor-3 is sufficient for lymphangiogenesis in transgenic mice. EMBO J [Internet]. 2001;20(6):1223 - 31. http://view.ncbi.nlm.nih.gov/pubmed/11250889 Tanja Veikkola et al., EMBO Journal 2001 (491.14 KB)
Tanja Veikkola et al., EMBO Journal 2001 (491.14 KB). Vascular endothelial growth factor-C-mediated lymphangiogenesis promotes tumour metastasis. EMBO J [Internet]. 2001;20(4):672 - 82. http://view.ncbi.nlm.nih.gov/pubmed/11179212 Stefano Mandriota et al., EMBO Journal 2001 (736.96 KB)
Stefano Mandriota et al., EMBO Journal 2001 (736.96 KB)